SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
HLS Therapeutics Inc. (HLTRF) , forward earnings yield 0.93%. PEG 0.51 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 107.0
- PEG Ratio 0.51 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 23/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HLTRF
Valuation Multiples
P/E (TTM)0.0
Forward P/E107.0
PEG Ratio0.51
Forward PEG0.51
P/B Ratio0.00
P/S Ratio1.79
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.40
Forward EPS (Est.)$0.03
Book Value / Share$0.00
Revenue / Share$1.79
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.93%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.04 |
$53.38M |
$-874.94K |
-1.6% |
| 2017 |
$-0.24 |
$75.08M |
$-6.1M |
-8.1% |
| 2018 |
$-0.92 |
$61.42M |
$-24.81M |
-40.4% |
| 2019 |
$-0.67 |
$54.16M |
$-19.55M |
-36.1% |
| 2020 |
$-0.48 |
$56.11M |
$-15.33M |
-27.3% |
| 2021 |
$-0.41 |
$60.01M |
$-13.12M |
-21.9% |
| 2022 |
$-0.73 |
$61.47M |
$-23.6M |
-38.4% |
| 2023 |
$-0.85 |
$63.07M |
$-27.53M |
-43.6% |
| 2024 |
$-0.62 |
$56.62M |
$-19.66M |
-34.7% |
| 2025 |
$-0.40 |
$56.47M |
$-12.65M |
-22.4% |
